Cite
Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
MLA
Papanicolaou, Genovefa A., et al. “Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-Cell or Solid-Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study.” Clinical Infectious Diseases, vol. 68, no. 8, Apr. 2019, pp. 1255–64. EBSCOhost, https://doi.org/10.1093/cid/ciy706.
APA
Papanicolaou, G. A., Silveira, F. P., Langston, A. A., Pereira, M. R., Avery, R. K., Uknis, M., Wijatyk, A., Wu, J., Boeckh, M., Marty, F. M., & Villano, S. (2019). Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. Clinical Infectious Diseases, 68(8), 1255–1264. https://doi.org/10.1093/cid/ciy706
Chicago
Papanicolaou, Genovefa A, Fernanda P Silveira, Amelia A Langston, Marcus R Pereira, Robin K Avery, Marc Uknis, Anna Wijatyk, et al. 2019. “Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-Cell or Solid-Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study.” Clinical Infectious Diseases 68 (8): 1255–64. doi:10.1093/cid/ciy706.